Mach7 Technologies (M7T) H2 2024 earnings summary

Executive summary

• Achieved record sales orders of AUD 61.3 million (up 52% year-over-year), driven by a transition to a subscription-based model and strong recurring revenue growth, with 83% of FY24 sales orders from Subscription and Maintenance contracts.

• Maintained positive operating cash flow and no debt, ending FY24 with a cash balance of AUD 26.2 million, the highest in four years.

• Focused on customer-centric innovation, integration, and cloud enablement to differentiate in a fragmented enterprise imaging market.

• Completed a large renewal program, securing foundational contracts with major customers such as the Hospital Authority of Hong Kong and Sentara Healthcare.

• Disciplined cost management kept opex growth under 15% amid growth investments.

Financial highlights

• FY24 revenue was AUD 29.1 million, down 3% year-over-year but in line with revised guidance; recurring revenue reached AUD 21.1 million, up 29%, now 72% of total revenue.

• CARR was AUD 27.9 million (up 35% year-over-year); ARR run rate at AUD 22 million (up 29%).

• Adjusted EBITDA was -AUD 2.0 million (FY23: AUD 2.5 million); NPATA was -AUD 1.2 million (FY23: AUD 7.2 million); NPAT was -AUD 8.0 million (FY23: -AUD 1.0 million).

• Record cash receipts from customers increased 42% to AUD 34.9 million; positive operating cash flow of AUD 3.5 million.

• Gross margin remained strong at 95%.

Outlook and guidance

• FY25 priorities include CARR and revenue growth of 15–25%, new customer acquisition, and continued expansion in APAC and North America.

• Planned AUD 2–3 million investment in people, systems, and tools to support innovation and scalability, included in opex guidance.

• Profitability expected to be delayed by a year due to investment, with ARR projected to cover opex by FY 2027.

• EBITDA guidance for FY25 is approximately AUD 1 million positive.